Efficacy and safety of sildenafil in the treatment of severe pulmonary hypertension in patients with hemoglobinopathies

• Published in: Haematologica (Roma) 2005-04, Vol.90 (4), p.452-458
• Main Authors: Derchi, G, Forni, GL, Formisano, F, Cappellini, MD, Galanello, R, D'Ascola, G, Bina, P, Magnano, C, Lamagna, M
• Format: Article
• Language: English
• Subjects: Administration, Oral; Adult; Anemias. Hemoglobinopathies; Biological and medical sciences; Blood Transfusion; Clinical Trials as Topic; Diseases of red blood cells; Dose-Response Relationship, Drug; Echocardiography, Doppler; Female; Hematologic and hematopoietic diseases; Hemoglobinopathies - complications; Humans; Hypertension, Pulmonary - complications; Hypertension, Pulmonary - drug therapy; Male; Medical sciences; Piperazines - adverse effects; Piperazines - therapeutic use; Pneumology; Priapism - chemically induced; Priapism - drug therapy; Pulmonary hypertension. Acute cor pulmonale. Pulmonary embolism. Pulmonary vascular diseases; Purines; Severity of Illness Index; Sildenafil Citrate; Sulfones; Vasodilator Agents - adverse effects; Vasodilator Agents - therapeutic use
• ISSN: 0390-6078; 1592-8721

Struttura Complessa di Cardiologia, Ospedali Galliera, Genoa, Italy. [e-mail] BACKGROUND AND OBJECTIVES: During the last decade new approaches to the treatment of pulmonary arterial hypertension (PH) have increased symptomatic relief and prolonged survival. PH is a common sequel of the hemoglobinopathies, thalassemia and sickle cell anemia, but the use of standard oral treatment options, such as calcium channel blockers, endothelin receptor antagonists, and long-term anticoagulation therapy, is limited because of toxicity and poor effectiveness. Sildenafil citrate is a selective and potent inhibitor of cGMP-specific phosphodiesterase-5 (PDE5) which promotes selective smooth muscle relaxation in lung vasculature and has been utilized successfully in the treatment of PH. The primary objective of this study was to evaluate the efficacy of sildenafil treatment in the control of PH in patients with hemoglobinopathies. DESIGN AND METHODS: In this study patients with hemoglobinopathies (thalassemia intermedia n=4; thalassemia major n=2; sickle thalassemia n=1) suffering from severe PH were treated with sildenafil citrate (50 mg b.i.d.) for periods ranging from 4 to 48 months. RESULTS: A significant decrease in pulmonary pressure and improvement in exercise capacity and functional class were observed in all patients. No significant adverse events were reported. INTERPRETATION AND CONCLUSIONS: These data, in a small group of patients, indicate that sildenafil citrate is effective in the treatment of PH in hemoglobinopathies that cannot be treated with alternative oral drugs and is well tolerated long-term at a daily dose of 100 mg, though studies including more patients may uncover toxicities and limitations of efficacy.